stockrow
Friday 6 November 2026
Export COAG’s income statement to Excel — free account
Hemab Therapeutics Holdings, Inc.
COAG Healthcare Biotechnology
48.60
3.03
+6.65%
Follow COAG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jun ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 2 | 2 | — | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | (74) | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | — | (59) | — | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | 8 | — | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | (73) | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | (73) | — | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | 451 | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | (457) | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | 454 | — | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Hemab Therapeutics Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SEPN Septerna, Inc. | $2.2B | — (loss-making) | — (loss-making) | +22,375.63% (above 0%: growing) | n/m | −9.01% (below 0%: shrinking) | 100.00% | (62.95%) | Compare |
| COAG Hemab Therapeutics Holdings, Inc. | $2.1B | — (loss-making) | — | — | n/m | — | — | 0.00% | |
| ZYME Zymeworks Inc. | $2.0B | — (loss-making) | 26.0× | −90.58% (below 0%: shrinking) | n/m | −385.53% (below 0%: shrinking) | (497.71%) | (918.95%) | Compare |
| FTRE Fortrea Holdings Inc. | $2.0B | — (loss-making) | — (loss-making) | −1.40% (below 0%: shrinking) | n/m | −33.96% (below 0%: shrinking) | 20.17% | 2.17% | Compare |
| TRAX First Tracks Biotherapeutics, Inc. | $1.9B | — (loss-making) | — | — | n/m | +55.91% (above 0%: growing) | — | 0.00% | Compare |
| HRMY Harmony Biosciences Holdings, Inc. | $1.9B | 10.5× | 9.9× | +12.30% (above 0%: growing) | −6.24% (below 0%: shrinking) | −29.42% (below 0%: shrinking) | 70.00% | 20.15% | Compare |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | — (loss-making) | 6.3× | −4.51% (below 0%: shrinking) | n/m | +231.84% (above 0%: growing) | 0.00% | (2.37%) | Compare |
| TRVI Trevi Therapeutics, Inc. | $1.8B | — (loss-making) | — | — | n/m | −73.77% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MRVI Maravai LifeSciences Holdings, Inc. | $1.8B | — (loss-making) | — (loss-making) | +10.14% (above 0%: growing) | n/m | +123.88% (above 0%: growing) | 35.31% | (44.97%) | Compare |
| Median of peers | $1.9B | — | 9.9× | +4.37% | — | −19.22% | 20.17% | (1.18%) |
Hemab Therapeutics Holdings, Inc. (COAG) Latest News
No news at this impact. Lower the threshold for more.